PURPOSE: To investigate the angiogenic changes in primary tumor tissue of renal cell carcinoma (RCC) patients treated with VEGF-targeted therapy. EXPERIMENTAL DESIGN: Phase II trials of VEGF pathway-targeted therapy given before cytoreductive surgery were carried out with metastatic RCC patients with the primary tumor in situ to investigate the necessity of nephrectomy. Primary tumor tissues were obtained and assessed for angiogenesis parameters. Results were compared with similar analyses on untreated tumors. RESULTS: Sunitinib or bevacizumab pretreatment resulted in a significant reduction of microvessel density in the primary tumor. Also, an increase in vascular pericyte coverage was found in sunitinib-pretreated tumors, consistent with efficient angiogenesis inhibition. Expression of several key regulators of angiogenesis was found to be suppressed in pretreated tissues, among which VEGFR-1 and VEGFR-2, angiopoietin-1 and angiopoietin-2 and platelet-derived growth factor-B. In addition, apoptosis in tumor and endothelial cells was induced. Interestingly, in sunitinib-pretreated tissues a dramatic increase of the number of proliferating endothelial cells was observed, which was not the case in bevacizumab-pretreated tumors. A positive correlation with the interval between halting the therapy and surgery was found, suggesting a compensatory angiogenic response caused by the discontinuation of sunitinib treatment. CONCLUSION: This study describes, for the first time, the angiostatic response in human primary renal cancers at the tissue level upon treatment with VEGF-targeted therapy. Discontinuation of treatment with tyrosine kinase inhibitors leads to accelerated endothelial cell proliferation. The results of this study contribute important data to the ongoing discussion on the discontinuation of treatment with kinase inhibitors.
PURPOSE: To investigate the angiogenic changes in primary tumor tissue of renal cell carcinoma (RCC) patients treated with VEGF-targeted therapy. EXPERIMENTAL DESIGN: Phase II trials of VEGF pathway-targeted therapy given before cytoreductive surgery were carried out with metastatic RCCpatients with the primary tumor in situ to investigate the necessity of nephrectomy. Primary tumor tissues were obtained and assessed for angiogenesis parameters. Results were compared with similar analyses on untreated tumors. RESULTS:Sunitinib or bevacizumab pretreatment resulted in a significant reduction of microvessel density in the primary tumor. Also, an increase in vascular pericyte coverage was found in sunitinib-pretreated tumors, consistent with efficient angiogenesis inhibition. Expression of several key regulators of angiogenesis was found to be suppressed in pretreated tissues, among which VEGFR-1 and VEGFR-2, angiopoietin-1 and angiopoietin-2 and platelet-derived growth factor-B. In addition, apoptosis in tumor and endothelial cells was induced. Interestingly, in sunitinib-pretreated tissues a dramatic increase of the number of proliferating endothelial cells was observed, which was not the case in bevacizumab-pretreated tumors. A positive correlation with the interval between halting the therapy and surgery was found, suggesting a compensatory angiogenic response caused by the discontinuation of sunitinib treatment. CONCLUSION: This study describes, for the first time, the angiostatic response in humanprimary renal cancers at the tissue level upon treatment with VEGF-targeted therapy. Discontinuation of treatment with tyrosine kinase inhibitors leads to accelerated endothelial cell proliferation. The results of this study contribute important data to the ongoing discussion on the discontinuation of treatment with kinase inhibitors.
Authors: Florry A Vyth-Dreese; Yeung-Hyen Kim; Trees A M Dellemijn; Ellen Schrama; John B A G Haanen; Eric Spierings; Els Goulmy Journal: J Immunol Methods Date: 2006-02-02 Impact factor: 2.303
Authors: Femke Hillen; Anouk van de Winkel; David Creytens; Anton H M Vermeulen; Arjan W Griffioen Journal: Melanoma Res Date: 2006-10 Impact factor: 3.599
Authors: Thomas Powles; Christian Blank; Simon Chowdhury; Simon Horenblas; John Peters; Jonathan Shamash; Naveed Sarwar; Ekaterini Boleti; Anju Sahdev; Tim O'Brien; Dan Berney; Luis Beltran; Paul Nathan; John Haanen; Axel Bex Journal: Eur Urol Date: 2011-05-17 Impact factor: 20.096
Authors: Robert J Motzer; Thomas E Hutson; Piotr Tomczak; M Dror Michaelson; Ronald M Bukowski; Olivier Rixe; Stéphane Oudard; Sylvie Negrier; Cezary Szczylik; Sindy T Kim; Isan Chen; Paul W Bycott; Charles M Baum; Robert A Figlin Journal: N Engl J Med Date: 2007-01-11 Impact factor: 91.245
Authors: Shom Goel; Dan G Duda; Lei Xu; Lance L Munn; Yves Boucher; Dai Fukumura; Rakesh K Jain Journal: Physiol Rev Date: 2011-07 Impact factor: 37.312
Authors: Axel Bex; Christian Blank; Wim Meinhardt; Harm van Tinteren; Simon Horenblas; John Haanen Journal: Urology Date: 2011-07-29 Impact factor: 2.649
Authors: A J Zurita; E Jonasch; X Wang; M Khajavi; S Yan; D Z Du; L Xu; M H Herynk; K S McKee; H T Tran; C J Logothetis; N M Tannir; J V Heymach Journal: Ann Oncol Date: 2011-04-04 Impact factor: 32.976
Authors: Maudy Walraven; Petronella O Witteveen; Martijn P J Lolkema; R van Hillegersberg; Emile E Voest; H M W Verheul Journal: Angiogenesis Date: 2010-12-29 Impact factor: 9.596
Authors: Xiaoen Wang; Liang Zhang; S Nahum Goldberg; Manoj Bhasin; Victoria Brown; David C Alsop; Sabina Signoretti; James W Mier; Michael B Atkins; Rupal S Bhatt Journal: J Transl Med Date: 2011-12-21 Impact factor: 5.531
Authors: Kriti Mittal; Henry Koon; Paul Elson; Pierre Triozzi; Afshin Dowlati; Helen Chen; Ernest C Borden; Brian I Rini Journal: Cancer Biol Ther Date: 2014-05-19 Impact factor: 4.742
Authors: S G C Kroeze; C Fritz; L Basler; E Gkika; T B Brunner; A L Grosu; M Guckenberger Journal: Strahlenther Onkol Date: 2019-02-08 Impact factor: 3.621
Authors: Patrycja Nowak-Sliwinska; Kari Alitalo; Elizabeth Allen; Andrey Anisimov; Alfred C Aplin; Robert Auerbach; Hellmut G Augustin; David O Bates; Judy R van Beijnum; R Hugh F Bender; Gabriele Bergers; Andreas Bikfalvi; Joyce Bischoff; Barbara C Böck; Peter C Brooks; Federico Bussolino; Bertan Cakir; Peter Carmeliet; Daniel Castranova; Anca M Cimpean; Ondine Cleaver; George Coukos; George E Davis; Michele De Palma; Anna Dimberg; Ruud P M Dings; Valentin Djonov; Andrew C Dudley; Neil P Dufton; Sarah-Maria Fendt; Napoleone Ferrara; Marcus Fruttiger; Dai Fukumura; Bart Ghesquière; Yan Gong; Robert J Griffin; Adrian L Harris; Christopher C W Hughes; Nan W Hultgren; M Luisa Iruela-Arispe; Melita Irving; Rakesh K Jain; Raghu Kalluri; Joanna Kalucka; Robert S Kerbel; Jan Kitajewski; Ingeborg Klaassen; Hynda K Kleinmann; Pieter Koolwijk; Elisabeth Kuczynski; Brenda R Kwak; Koen Marien; Juan M Melero-Martin; Lance L Munn; Roberto F Nicosia; Agnes Noel; Jussi Nurro; Anna-Karin Olsson; Tatiana V Petrova; Kristian Pietras; Roberto Pili; Jeffrey W Pollard; Mark J Post; Paul H A Quax; Gabriel A Rabinovich; Marius Raica; Anna M Randi; Domenico Ribatti; Curzio Ruegg; Reinier O Schlingemann; Stefan Schulte-Merker; Lois E H Smith; Jonathan W Song; Steven A Stacker; Jimmy Stalin; Amber N Stratman; Maureen Van de Velde; Victor W M van Hinsbergh; Peter B Vermeulen; Johannes Waltenberger; Brant M Weinstein; Hong Xin; Bahar Yetkin-Arik; Seppo Yla-Herttuala; Mervin C Yoder; Arjan W Griffioen Journal: Angiogenesis Date: 2018-08 Impact factor: 9.596
Authors: Monika Haemmerle; Justin Bottsford-Miller; Sunila Pradeep; Morgan L Taylor; Hyun-Jin Choi; Jean M Hansen; Heather J Dalton; Rebecca L Stone; Min Soon Cho; Alpa M Nick; Archana S Nagaraja; Tony Gutschner; Kshipra M Gharpure; Lingegowda S Mangala; Rajesha Rupaimoole; Hee Dong Han; Behrouz Zand; Guillermo N Armaiz-Pena; Sherry Y Wu; Chad V Pecot; Alan R Burns; Gabriel Lopez-Berestein; Vahid Afshar-Kharghan; Anil K Sood Journal: J Clin Invest Date: 2016-04-11 Impact factor: 14.808